Treatment of large bone defects is currently performed using mainly autograft or allograft bone. There are important drawbacks to bone grafting, such as limited availability, donor site morbidity in the case of autograft and inferior performance of allografts. Therefore, there is a great need for a suitable bone graft substitute. In order to evaluate efficiently newly developed biomaterials and factors intended for orthopaedic surgery, the bone chamber is a very suitable model. To allow longitudinal investigation of bone growth with μCT, a new bone chamber made of radiolucent polyether ether ketone (PEEK) was developed and studied for its feasibility. Therefore, PEEK bone chambers were placed on rat tibiae, and filled with vehicle (Matrigel without growth factors, negative controls), with bone morphogenetic protein 2 (BMP-2, positive controls), or a mix of growth factors combining BMP-2, vascular endothelial growth factor and the chemokine stromal cell-derived factor 1α, all laden on gelatin microspheres for controlled release (combined growth factors). Growth factor presence led to a significant increase in bone formation after 8 weeks, which subsided after 12 weeks, underlining the importance of longitudinal analysis. We conclude that the PEEK-bone chamber is a suitable translational animal model to assess orthotopic bone formation in a longitudinal manner.
Introduction
The majority of large bone defects are currently treated with auto-or allograft bone, which both have important drawbacks such as limited availability of donor bone and donor site morbidity for autograft, whereas allograft bone may lead to inferior performance (Khan et al., 2005; Silber et al., 2003) . To reduce the need for auto-or allograft bone, tissue-engineered bone-constructs have become an important pillar in the field of regenerative medicine. A broad spectrum of biomaterials is currently under investigation in different in vitro and in vivo models for their suitability to function as a scaffold for bone regeneration (Barradas et al., 2011; Van der Stok et al., 2011) . One of the in vivo models to study a material's osteopromotive quality is the bone chamber. The main advantages of bone chambers are that they are relatively easy to implant (they are non-weight bearing) and the osteogenicity of biomaterials can be measured as the total amount of bone formed and the bone height reached in the chamber. In the past, many bone chambers were made of titanium (Belfrage et al., 2012; Hannink et al., 2006; Mathijssen et al., 2012; Wang and Aspenberg, 1994) , a very strong and bone-friendly material which, however, is unsuitable for accurate evaluation of bone formation with micro computed tomography (μCT), as the titanium creates large image artefacts. We developed a new radiolucent bone chamber based on polyether ether ketone (PEEK). PEEK has been used in medical devices and has good mechanical characteristics and biocompatibility (Toth et al., 2006) .
Growth factors are increasingly applied in regenerative medicine to improve construct characteristics. For example, bone morphogenetic protein 2 (BMP-2) is known to induce osteogenesis (Garrison et al., 2010) and can be used in a bone chamber model (Jeppsson et al., 1999) . Application of vascular endothelial growth factor (VEGF) leads to angio-and vasculogenesis (Ferrara et al., 2003) , whereas the chemokine stromal cell-derived factor 1α (SDF-1α) can attract multipotent stromal cells (MSCs) (Hattori et al., 2001) . Even though SDF-1α is known to play an important role in stem cell homing, its functionality in terms of osteogenic differentiation in tissue engineered constructs in vivo is not clear (Eman et al., 2014) . Some authors have reported a synergistic effect of SDF-1α addition to BMP-2 laden scaffolds (Liu et al., 2013; Ratanavaraporn et al., 2011) . These growth factors, that have short half-life times, can be laden on 36 www.ecmjournal.org MT Poldervaart et al.
The PEEK bone chamber gelatin microspheres (GMP) for controlled release to ensure a prolonged presence (Patel et al., 2008b) . Gelatin is a natural product that is used in many FDA-approved devices. Growth factor encapsulation in GMPs is based on electrostatic interactions with the gelatin, as well as the gelatin degradation rate (Ikada and Tabata, 1998; Patel et al., 2008a; Patel et al., 2008b; Yamamoto et al., 2001) . The main advantages of the GMPs are the diffusional loading of growth factors and the non-covalent nature of the interaction between gelatin and growth factor, thus avoiding chemical reactions that could damage the protein.
Furthermore, GMPs are non-cytotoxic, biodegradable and they have previously been used to deliver growth factors such as BMP-2, transforming growth factor β1 (TGFβ1) and fibroblast growth factor (FGF) (Leeuwenburgh et al., 2010; Yamamoto et al., 2003) . The aim of this study was to investigate the applicability and effectivity of the PEEK bone chamber as a model to monitor orthotopic bone formation in a longitudinal manner. To that end, bone chambers were bilaterally implanted in the tibiae of rats, and growth factor-induced bone formation was measured at multiple time points with in vivo μCT scans.
Materials and Methods

Study design
The objective of this study was to investigate the applicability and effectivity of the PEEK bone chamber model to monitor orthotopic bone formation in a longitudinal manner. To that end, a controlled laboratory experiment was performed. Bone chambers were bilaterally implanted in the tibiae of rats, and growth factor-induced bone formation was measured at multiple time points using in vivo μCT. All samples were randomly allocated, and implanted and analysed by researchers who were blinded for the experimental groups.
Study endpoints and statistical methods were prospectively selected and documented. Sample size was calculated with a power analysis to achieve reliable measurement of the effect, and this number did not change during the course of the study. The standard guidelines for humane endpoints in animal experiments were applied, though none of the animals met these criteria. All data were included in the analysis and no outliers were detected.
Bone chamber preparations
The experimental design is depicted in Table 1 . Bone chambers were placed bilaterally on the tibiae of 10 rats, then filled with 20 μL Matrigel (growth factor-reduced, cat no. 354230, BD Biosciences, Franklin Lakes, NJ, USA; negative controls), 20 μL Matrigel with 100 μg/ mL BMP-2 (InductOS, Wyeth, Cambridge, MA, USA; positive controls), or 20 μL Matrigel with 100 μg/mL BMP-2, 25 μg/mL VEGF and 25 μg/mL SDF-1α (R&D Systems, Minneapolis, MN, USA; combined growth factors), each laden on GMP for sustained release. GMP were fabricated as described previously (Poldervaart et al., 2014) . Combined growth factor containing chambers (n = 10) were implanted in one tibia, and were matched with either a positive (n = 5) or negative control (n = 5) chamber in the other tibia of the animal to allow paired data analysis.
Production of the bone chambers
The design of the PEEK bone chamber was an adaptation to the titanium bone conduction chamber (BCC) developed by Aspenberg and colleagues (van der Donk et al., 2001) , that consists of two parts. The inner part is a cylindrical chamber of 7 × 2 mm Ø (≈ 22 mm 3 ), covered by a cap (Fig.  1) to create a confined chamber. Both parts were produced from solid PEEK plates (Vink Kunststoffen, Didam, the Netherlands). The design files of the PEEK bone chambers can be obtained by contacting the corresponding author. 
Surgical technique, animals and operations
Implantation of bone chambers
Rats were placed in a supine position, both medial knee regions were shaved and disinfected. An elastic band, placed in the groin region, functioned as a tourniquet in order to temporarily reduce blood flow to the operated leg. Subsequently a 1 cm longitudinal incision was made over the medial plane of the proximal tibia. Underlying fascia and muscles were gently pushed to the medial side until the bone was fully exposed. A guiding hole was drilled with a thin bone drill (0.7 mm Ø) approximately 2 mm below the proximal growth plate and 1 mm anterior to the insertion of the semitendinosis and gracilis tendons. The guiding hole was enlarged up to 2 mm Ø by using 1, 1.5 and 2 mm diameter drill bits. Then the bone chambers were screwed into the hole, until the side openings reached the height of the adjacent cortex. After placement, the chambers were filled according to a randomised scheme.
The cap was placed over the bone chamber before the skin was sutured using Vicryl 4-0. Postoperatively, the animals were weighed and given a subcutaneous injection of buprenorphine (0.05 mg/kg, Temgesic, Schering-Plough/ Merck, Whitehouse Station, NJ, USA) twice a day for the first three days after surgery. Fluorochrome labels were administered at 4 (tetracycline, 25 mg/kg bodyweight), 8 (calcein, 25 mg/kg body weight), and 11 weeks (xylenol orange, 90 mg/kg body weight) to monitor the onset of bone formation (van Gaalen et al., 2010) . The 8 week label was not incorporated in any of our samples or control tissue and therefore was excluded from the fluorochrome analysis.
Clinical evaluation of the procedure All bone chambers performed well and remained at the correct location during the entire study. The animals rapidly recovered and mobilised, limping was observed in the first week after surgery only, and no complications occurred.
μCT evaluation
Immediately after surgery, a baseline in vivo μCT scan was acquired of all implanted bone chambers using a SkyScan 1176 scanner (Bruker μCT, Kontich, Belgium), and after 4, 8 and 12 weeks subsequent scans were perfomed. An 18 μm-resolution protocol was used (65 kV, 270 ms exposure time, 1.0 mm Al filter, 0.5° rotation step), resulting in a 9 min scan. After explantation of the subcutaneously implanted biphasic calcium phosphate scaffolds (BCP-1150 containing 82 % HA and 18 % TCP, Xpand, Bilhoven, the Netherlands), ex vivo μCT scans were acquired using a 9 μm-resolution protocol (65 kV, 1320 ms exposure time, 1.0 mm Al filter, 0.32° rotation step, 53 min scan). All μCT images were reconstructed using volumetric reconstruction software NRecon version 1.5 (Bruker μCT).
To measure bone formation inside the bone chamber calcified tissue was distinguished from non-calcified tissue and noise by segmentation. Therefore, grayscale images were reconstructed by an automated algorithm using local thresholds (3D Calculator v0.9 (Waarsing et al., 2004) ). Subsequently, in the resulting 3D dataset (consisting of stacked black and white cross-sections) bone was measured inside a cylindrical volume of interest capturing the inner volume of the bone chambers using CTAnalyser version 1.11 software (Bruker μCT). All analysis and segmentation were performed on blinded data sets.
Histology
The rats were killed after 12 weeks using an injection of Euthanasol (Virbac, Fort Worth, TX, USA). Bone chambers were retrieved, fixed in 4 % buffered formalin, dehydrated using an ethanol series, and embedded in polymethylmethacrylate (MMA). Samples were sawed centrally into approximately 25 μm thick sections using a sawing microtome (Leica, Nussloch, Germany) and stained with methylene blue and basic fuchsin for histomorphometric analysis. High-resolution digital pictures of the samples were taken using transmitted light microscopy (Olympus-BX50, Olympus, Zoeterwoude, the Netherlands).
Statistical analysis
Bone formation was analysed by SPSS version 20 software (IBM, Chicago, IL, USA). Combined growth factor filled chambers (n = 10) were implanted in one tibia, and were matched with either a positive (n = 5) or negative control (n = 5) chamber in the other tibia of the animal to allow paired data analysis. Differences between treatments were analysed with a paired t-Test. Post-hoc testing to correct for the number of tests was performed using a Bonferroni correction. All bars represent mean values, with standard deviations depicted in the error bars. Significance between treatments was assumed when p < 0.05.
Results
Assessment of tissue ingrowth and bone formation in the PEEK chambers
Bone formation in the chambers, as seen on μCT, was confirmed by methylene blue and basic fuchsin staining on the MMA-embedded sections (Fig. 2) . In the controls, that did not contain growth factors, little bone was formed ( Fig. 2A, C) , whereas the chambers were filled with bone that reached to the top of the chamber in the growth factor-containing chambers (Fig. 2B, D) . The 4-week fluorochrome label (green) was not present in the bone in the chambers, the 11-week label (red) was. This confirms late onset of bone formation, which is in accordance with the μCT measurements and previous findings in spinal cassettes (Geuze et al., 2012) . Both labels were present in the cortical bone and epiphysis of the tibia, indicating normal active bone deposition during the entire study period.
The baseline μCT directly after surgery confirmed that no bone fragments were present in the chambers after implantation and that they were correctly placed, bicortically, on the tibiae. In the μCT scan after 4 weeks MT Poldervaart et al.
The PEEK bone chamber of implantation, no bone formation was present, but bone ingrowth was clearly visible by μCT from 8 weeks onwards (Fig. 3) . Quantification of the bone volumes revealed that the chambers that contained the combination of growth factors showed significantly higher bone formation at 8 weeks than the empty chambers (p = 0.04). At 12 weeks this difference was no longer statistically significant (p = 0.06). Both the BMP-2 and combined growth factorladen chambers contained bone volumes indistinguishable from each other at 8 and 12 weeks.
Discussion
This study showed that the PEEK bone chamber is a suitable model to assess (growth factor-induced) orthotopic bone formation. All chambers were easily implanted bicortically (without surgical failures), remained in the correct position, and the animal recovered within days after the surgery. The importance of longitudinal analysis of bone formation was underlined by the outcomes of this experiment, namely the significant difference in bone formation between the control and growth factor-laden chambers present at 8 weeks after implantation, which was no longer statistically significant at 12 weeks. We hypothesise that after 8 weeks, remodelling of the newly formed bone started playing a larger role than de novo bone formation, lowering the increase in bone volume and leading to larger inter-individual variations. Also, due to the small volume of the chamber, a plateau-phase was often already reached before 12 weeks of implantation.
Longitudinal assessment of bone formation enabled detection of the significant differences in bone volume between the treatments, which would have been missed if only an end-point measurement had been performed. Inclusion of the gold-standard treatment for bone augmentation, which is the application of autologous bone, was not chosen here, as this would complicate the analysis of new bone ingrowth. Bone induction by BMP-2 in rats is well studied with respect to dosage and kinetics, and so this was taken as a positive control. When we compared the BMP-2-laden chambers to the combined growth factor chambers, no differences were seen. The BMP-2 that was added to the chambers appeared to induce optimal bone formation in this time-frame and setting. Because the necessary cells were most likely able to migrate into the chambers through the openings at the cortical level, there may have been a limited need for VEGF and SDF-1α addition. This would mean that, in order to assess growth factor synergy, the volume of the chambers should be enlarged to a size where vascularisation is critical for bone formation. Furthermore, the concentration of BMP-2 was based on findings in the literature (Jang et al., 2012) , and was supraphysiological. Together with the confined space offered by the chamber, this may have led to maximal bone induction, hereby masking possible synergistic or additive effects of the other growth factors, that are well established for VEGF (Kanczler et al., 2010; Kempen et al., 2009 ) and also reported for SDF-1α (Ratanavaraporn et al., 2011) .
GMPs were applied because of their beneficial effects seen in our previous studies (Kempen et al., 2008) . In this experimental set-up the release of the growth factors was also expected to be gradual, because Matrigel is known to retain growth factors (Gao et al., 2009) . The use of GMPs is reported for BMP-2 and VEGF delivery (Patel et al., 2008b) , and there is evidence that controlled release of SDF-1α leads to improved angiogenesis (Kimura and Tabata, 2010) . Together, this argues against an insufficient availability of the individual growth factors in the combined growth factor-laden chambers.
The limitations of this study need to be optimised further, before the PEEK bone chamber can be applied in large animal models and translational research to screen the bone forming capacity of novel materials. First, the size of the bone chambers could be increased to introduce the need for early scaffold vascularisation in this model. Then, application of bone chambers at multiple implantation sites could be optimised. In the current setting, bone chambers are not weight bearing, resulting in less variation due to implant movement, but also complicating translation to weight bearing orthotopic implantation sites. When these limitations are addressed and the model is further optimised, implant components such as matrices and biologicals can be screened in small and large animal models, which is an important step to translate in vitro findings to clinical applications.
Conclusion
The PEEK bone chamber proved to be a suitable model to investigate orthotopic bone formation in a longitudinal manner. Our results showed that in all growth factor-laden chambers bone formation increased significantly compared to control.
